ImmunityBio Inc. (NASDAQ:IBRX) is one of the 13 Stocks Under $5 With High Upside Potential. ImmunityBio Inc. (NASDAQ:IBRX) ...

Valo Health Inc. has disclosed sphingosine 1-phosphate receptor 1 (S1P1 receptor; EDG1) agonists reported to be useful for the treatment of multiple sclerosis, psoriasis, amyotrophic lateral sclerosis ...

Finding an effective, safe medication to control itch is essential to maximize patient comfort. Because Zenrelia does not require a loading dose and is administered once daily, Zenrelia may help impro ...

ImmunityBio Inc. (NASDAQ:IBRX) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. On June 2, ImmunityBio Inc. (NASDAQ:IBRX) announced that it attained Expanded Access ...

ImmunityBio Inc. scored a win earlier this month. The Culver City-based company announced that the U.S. Food and Drug Administration has granted “expanded ...

The lymphopenia opportunity was until recently under-emphasized by ImmunityBio. For example, in their general corporate presentation from January of this year, the word "lymphopenia" was not ...

“Lymphopenia has long been recognized as a major driver and predictor of early mortality in cancer—yet until now, it has remained unaddressed,” said Patrick Soon-Shiong, MD, founder, executive ...

ImmunityBio, Inc. today announced results presented at ASCO 2025 of the first known treatment for lymphopenia with ANKTIVA and CAR-NK therapy. This data supports that reversal of lymphopenia, a ...

CULVER CITY, Calif., June 03, 2025--ImmunityBio, Inc. (NASDAQ: IBRX) today announced results presented at ASCO 2025 of the first known treatment for lymphopenia with ANKTIVA and CAR-NK therapy ...

Lymphopenia weakens the immune system, increases infection risk, and is linked to early death across many cancer types 5. Low Absolute Lymphocyte Count (ALC) is a recognized poor prognostic marker.